IFNB1 and myeloid sarcoma: In addition, another study demonstrated that MS patients treated with IFN-β or methylprednisolone had higher serum IL-35 levels, which suggested that the clinical therapeutic benefits of these drugs might be partly induced by the upregulation of IL-35 (89).